Q-omics provides the consensus-scored GGTLC5P profile across patient tissues and cancer cell-line models. GGTLC5P expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, GGTLC5P is differentially expressed in 6, with the highest sampling consensus in THCA. Additionally, GGTLC5P RNA expression shows 5,194 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, THCA, and STAD as cancer lineages where GGTLC5P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GGTLC5P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GGTLC5P survival associations across molecular data types. GGTLC5P RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GGTLC5P RNA expression–survival associations across cancer types. High GGTLC5P expression shows unfavorable associations in KICH, CHOL, DLBC, LUSC and LIHC, but favorable associations in BLCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for GGTLC5P RNA expression.
This table summarizes GGTLC5P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for GGTLC5P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GGTLC5P shows lower tumor expression in LUSC, LUAD and KICH and higher tumor expression in THCA, UCEC and KIRC. The THCA box plot shows higher GGTLC5P RNA expression in tumor versus normal tissue (log2 FC = +0.316, t-test p < 0.001).
This table shows molecular features associated with GGTLC5P in patient tissues and cancer cell lines. In patient samples, GGTLC5P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
